Hyposmia (or the reduction in the ability to detect odors) can occur for a number of reasons, but viral infection of the upper respiratory tract is one of the most common causes.

Studies have found that more than 30% of people experience a loss of smell after COVID-19 infection.

Advanced ENT & Allergy

Contact our Clinical Research Team to learn more:

Research@AdvancedENTandAllergy.com

or call 502-893-0159 x1184

Have you experienced a loss of sense of smell due to COVID or other viral infection?

Ask your doctor about the **Loss of Smell Study**. You may be eligible for this trial investigating a treatment for the loss of smell following COVID or other viral infection.

What is CYR-064?

CYR-064 is a nasal spray drug that was developed as a treatment for subjects experiencing a loss of sense of smell after viral infection. The active ingredient, theophylline, is a natural chemical that is derived from two plants and is commonly used in the treatment of asthma and COPD.

How many people can participate in the Loss of Smell Study?

About 150 people will take part in this study at approximately 12 research sites in the United States.

Who can participate in the Loss of Smell Study?

There are many factors that will affect whether a person can participate in the Loss of Smell Study. Some of the criteria to participate include:

- Between the ages of 18 to 65 years old
- Have a clinical diagnosis of hyposmia for 6 or more months and less than 2 years that was reported at the onset of a viral infection.
- Willing to administer the study drug (nasal spray) to yourself twice daily.

There are more study criteria that can be determined by your study doctor.

How long will I be in this research?

Your participation in the Loss of Smell Study is expected to last for approximately 29 weeks. This includes a 4-week screening period to evaluate if you are right for the study, followed by a 24-week study treatment period, and a 1 week follow up after you've completed the study.

Why is the Loss of Smell trial being conducted?

There is no long-term effective treatment option for post-viral hyposmia. CYR-064 has been studied in pre-clinical models for safety and effectiveness. Those studies raised no areas of concern at the dose range proposed in the clinical study. For this product to be available for treating post-viral hyposmia, a clinical trial must take place. Clinical trials are a required part for making new drugs available to patients. Participation in the Loss of Smell Study will help us to understand more about CYR-064 and will play a crucial role in deciding if it should be made available in the future to patients with a diagnosis similar to yours.

How will I benefit from participating in the Loss of Smell Study?

Although there is no guarantee that you will benefit from participating, there is the potential for your sense of smell to return to normal. For those who are eligible and choose to partici- pate, their data along with additional trials will help contribute to a future submission to the regulatory authorities who will decide whether CYR-064 should be made available to patients suffering from post-viral hyposmia. There is also monetary compensation available should you choose to participate in the study.

What if I'm interested in participating in the Loss of Smell Study?

If you are interested in being considered for the Loss of Smell Study or have questions, talk to your doctor or the research team using the contact information listed below: